Search
IMC-1C11
go.drugbank.com/drugs/DB06101ExperimentalIMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma. … It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation.
Levotofisopam
go.drugbank.com/drugs/DB19073InvestigationalLevotofisopam is under investigation in clinical trial NCT01519687 (Study of Levotofisopam 50 Mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout).
TAK-611
go.drugbank.com/drugs/DB17644InvestigationalTAK-611, formerly known as SHP611, is a recombinant human arylsulfatase A. First developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy.
RXC008
go.drugbank.com/drugs/DB33985ExperimentalRXC008 is a small molecule drug. RXC008 is under investigation in clinical trial NCT07832435 (A Phase 2, Placebo-Controlled Study of Oral RXC008 for Crohn's Strictures).
1,4-Dithiothreitol
go.drugbank.com/drugs/DB04447ExperimentalA reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]
Biapenem
go.drugbank.com/drugs/DB13028InvestigationalIt is a carbapenem antibiotic with a methyl group on the 1-beta position, which gives it stability against degradation by dehydropeptidase I.[A275008]
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseMDX-214
go.drugbank.com/drugs/DB06110ExperimentalIt is developed for the treatment of EGF-R overexpressing cancers. … MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector
Paliroden
go.drugbank.com/drugs/DB05454InvestigationalIt is indicated for use in Alzheimer's Disease and Parkinson’s.
Ioxilan
go.drugbank.com/drugs/DB09135ApprovedWithdrawnIoxilan is a tri-iodinated diagnostic contrast agent.
Categories: Compounds used in a research, industrial, or household settingTSHA-118
go.drugbank.com/drugs/DB16996ExperimentalTSHA-118 is a self-complementary AAV9 gene replacement therapy designed to express a human codon-optimized CLN1 transgene for the treatment of CLN1 disease.